Document Detail


Pathologic response to preoperative therapy: does it mean what we think it means?
MedLine Citation:
PMID:  19326170     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Tumors treated with preoperative chemotherapy or radiation often demonstrate evidence of response in the resection specimen. Pathologic response is often interpreted as a surrogate for recurrence or survival outcomes. With a valid surrogate for long-term outcomes, investigators can explore treatment strategies with immediate endpoints. The financial and time costs of trials measuring recurrence and survival may be lessened by using short-term pathologic outcomes as an endpoint. This review is intended to examine the current status of pathologic response as a surrogate for tumor behavior. We address questions regarding the definitions of pathologic response, as well as the current literature regarding the meaning of pathologic response for some common tumor types. We explore some of the potential confounding effects that may explain the frequent discordance between tumor response and patient outcomes. In addition, we address some alternative strategies to gauge the response of a tumor to preoperative therapy.
Authors:
John C Mansour; Roderich E Schwarz
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Review     Date:  2009-03-27
Journal Detail:
Title:  Annals of surgical oncology     Volume:  16     ISSN:  1534-4681     ISO Abbreviation:  Ann. Surg. Oncol.     Publication Date:  2009 Jun 
Date Detail:
Created Date:  2009-05-05     Completed Date:  2009-06-18     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9420840     Medline TA:  Ann Surg Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1465-79     Citation Subset:  IM    
Affiliation:
Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center at Dallas, USA. john.mansour@utsouthwestern.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents / administration & dosage
Chemotherapy, Adjuvant
Combined Modality Therapy
Humans
Neoadjuvant Therapy
Neoplasms / mortality,  pathology*,  physiopathology,  therapy*
Neoplastic Processes
Radiotherapy, Adjuvant
Remission Induction
Survival Analysis
Grant Support
ID/Acronym/Agency:
UL1 RR024982/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
0/Antineoplastic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Correlation between connexin 26 expression and poor prognosis of esophageal squamous cell carcinoma.
Next Document:  The Use of F-18 Choline PET in the Assessment of Bone Metastases in Prostate Cancer: Correlation wit...